Latest News

  • Biology-Based Diagnostic Criteria For Parkinson’s Disease Research

    Diagnostics World | Scientists from a trio of countries are calling for a new, more comprehensive way of classifying Parkinson’s disease for diagnostic research purposes that considers an individual’s biology. The disorder might thereby be detected before patients have any symptoms, as is now the case for cancer and diabetes.

    Mar 14, 2024

  • Proteomics Approach Working Its Way To The Clinic For Stubborn Cancers

    Diagnostics World | For roughly half of patients with recurrence of often-deadly glioblastoma multiforme (GBM), their tumors are characterized by cells that look a lot like healthy neurons. The mimicry trick was discovered by proteomics, which has opened a view to tumor alterations unavailable through genetics alone.

    Mar 12, 2024

  • GO Chip Finds Biomarkers Of Response To Lung Cancer Treatment

    Diagnostics World | Biomedical engineers have a significant role to play in the development and optimization of liquid biopsies to further precision oncology. Although molecular profiling of tumors has entered mainstream clinical practice, the wait time for identifying the best treatment for individual patients could be shortened by blood-testing devices designed to efficiently capture circulating tumor cells (CTCs) and cancer-specific protein markers on their surface.

    Mar 7, 2024

  • Priming Agents Could Take Liquid Biopsies To A Whole New Level

    Diagnostics World | A team of researchers from Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard are developing priming agents to temporarily boost levels of cell-free DNA (cfDNA) for cancer diagnostics. It’s an entirely new concept that could do for liquid biopsies what contrast agents have done for ultrasound and MRI.

    Mar 6, 2024

  • ‘Fragmentomics’ Approach Catches Cancers Earlier In The Blood

    Diagnostics World | A machine learning method dubbed A-PLUS (Alu Profile Learning Using Sequencing) recently demonstrated its ability to pick up cancers earlier and with smaller blood draws than is required for whole genome sequencing. This makes possible a future where people might get annual blood draws to check for cancer based on the “fragmentation pattern” of cell-free DNA (cfDNA) circulating in their blood.

    Mar 5, 2024

  • PathAI Extends Roche Partnership, AI-Enabled Diagnostics Interpretations, More

    Diagnostics World | Owkin-Amazon Web Services partner on AI-assisted diagnostics, Diagnexia announced a significant collaborative agreement with Aga Khan University Hospital (AKUH), Nairobi; X-trodes announced that the U.S. Food and Drug Administration has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M); PathAI has announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion diagnostics; and more.

    Feb 29, 2024